Cargando…

Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo

Norrby K, Nordenhem A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS 2010; 118: 949–57. Tumors are angiogenesis dependent and vascular endothelial growth factor-A (VEGF-A), a heparin-binding protein, is a key angiogenic factor. As...

Descripción completa

Detalles Bibliográficos
Autores principales:	NORRBY, KLAS, NORDENHEM, ARVID
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2010
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003896/ https://www.ncbi.nlm.nih.gov/pubmed/21091776 http://dx.doi.org/10.1111/j.1600-0463.2010.02635.x

Ejemplares similares

Structural Characterization of the Low-Molecular-Weight Heparin Dalteparin by Combining Different Analytical Strategies
por: Bisio, Antonella, et al.
Publicado: (2017)

Does dalteparin PROTECT better than heparin?
por: Przybysz, Thomas, et al.
Publicado: (2011)

Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: an in vivo study
por: Artang, Ramin, et al.
Publicado: (2009)

Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study
por: Inamo, Yasuji, et al.
Publicado: (2014)

A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris
por: Amane, Hanmant S., et al.
Publicado: (2011)

Effect of a Direct Thrombin Inhibitor Compared with Dalteparin and Unfractionated Heparin on Human Osteoblasts
por: Winkler, Tobias, et al.
Publicado: (2011)

Heparin/low molecular weight heparins: Thrombocytopenia: 7 case reports
Publicado: (2021)

Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis
por: ALBERTSSON, PER, et al.
Publicado: (2012)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels
por: Bengalorkar, Girish M., et al.
Publicado: (2011)

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
por: Chen, Jianle, et al.
Publicado: (2019)

A meta-analysis of bridging anticoagulation between low molecular weight heparin and heparin
por: Tao, Ende, et al.
Publicado: (2020)

Arterial indications for the low molecular weight heparins
por: Ageno, Walter, et al.
Publicado: (2001)

AZD-1222/dalteparin-sodium/heparin: Venous thrombosis, thrombocytopenia and lack of efficacy: 5 case reports
Publicado: (2021)

Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar
por: Locke, Charles FS, et al.
Publicado: (2005)

Low-Molecular-Weight Heparin and Unfractionated Heparin Decrease Th-1, 2, and 17 Expressions
por: Huang, Jing-Ning, et al.
Publicado: (2014)

Is the Incidence Trend of Heparin-Induced Thrombocytopenia Decreased by the Increased Use of Low-Molecular-Weight-Heparin?
por: Al-Eidan, Fahad A S
Publicado: (2015)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023)

Molecular Targeting of VEGF with a Suramin Fragment–DOCA Conjugate by Mimicking the Action of Low Molecular Weight Heparins
por: Park, Jooho, et al.
Publicado: (2020)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

The Effect of Low Molecular Weight Heparins on Fracture Healing
por: Kapetanakis, Stylianos, et al.
Publicado: (2015)

Low-molecular weight heparin infusion as anticoagulation for haemodialysis
por: Wong, Steve Siu-Man, et al.
Publicado: (2016)

COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
por: Perna, Alessandra F., et al.
Publicado: (2020)

Management of intentional overdose of low-molecular-weight heparin
por: Lu, Clara, et al.
Publicado: (2022)

Effect of Low Molecular Weight Heparins (LMWHs) on antiphospholipid Antibodies (aPL) – Mediated Inhibition of Endometrial Angiogenesis
por: D'Ippolito, Silvia, et al.
Publicado: (2012)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain
por: Yu, Lumeng J., et al.
Publicado: (2021)

Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients
por: Li, Guowei, et al.
Publicado: (2015)

Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis
por: Lazrak, Hind Harrak, et al.
Publicado: (2017)

Patients’ Plasma Activity of Heparin, low-Molecular-Weight Heparin or no Anticoagulants on Urine Based DOAC Test Strips
por: Harenberg, Job, et al.
Publicado: (2022)

Production of a heparin-binding angiogenesis factor by the embryonic kidney
Publicado: (1986)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

Update on the clinical use of the low-molecular-weight heparin, parnaparin
por: Camporese, Giuseppe, et al.
Publicado: (2009)

The potential benefits of low-molecular-weight heparins in cancer patients
por: Robert, Francisco
Publicado: (2010)

Diffuse alveolar hemorrhage associated with low molecular weight heparin
por: Hayashi, Shinichi, et al.
Publicado: (2013)

Low molecular weight heparin use in unexplained recurrent miscarriage
por: Yuksel, Halide, et al.
Publicado: (2014)

Use of low-molecular-weight heparin in COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2020)

Low molecular weight heparin in COVID-19: benefits and concerns
por: Makarem, Adham, et al.
Publicado: (2023)

The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model
por: Debergh, I, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ld5r1ec63cvc4uk7qp0qnpc010